Is there a place for anti-nucleosome antibody assessment in scleroderma?

Burlui, Alexandra; Pharmacy, Iaşi; Cardoneanu, Anca; Macovei, Luana Andreea; Arhire, Lidia Iuliana; Graur, Mariana; Rezuş, Elena

doi:10.37897/rjr.2018.4.4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Raynaud's phenomenon marks the onset of the disease in the majority of cases and contributes to the appearance of functional hindrance and a decreased quality of life (10). While the initial trigger of vascular damage in SSc remains a matter of debate, recent A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study evidence indicates that autoantibody profiles, abnormal cytotoxic T cell activity and reperfusion injury all participate in the development of SSc-related vasculopathy (11)(12)(13). It has also been stated that oxidative stress may play a role in the pathomechanisms of scleroderma, similar to other pathologies (1,14,15).…”

Section: Introductionmentioning

confidence: 99%

A patient‑centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single‑center observational study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare and complex autoimmune disease associated with poor vital and functional outcomes. The functional hindrance in patients derives from various disease-specific manifestations, including Raynaud's phenomenon and digital ulcers (DUs). Bosentan is an endothelin receptor antagonist capable of preventing the appearance of new DUs in patients with scleroderma. The present study aimed to evaluate the effects of Bosentan on the severity of Raynaud's phenomenon, DU-related symptoms and functional impairment during the first year of treatment. A prospective study that included adult patients with SSc admitted to the Rheumatology Department between January 2016 and January 2017 that were candidates for Bosentan therapy, was performed. All patients were asked to evaluate the burden of symptoms secondary to Raynaud's and DUs using a visual analogue scale (VAS), whereas functional hindrance was assessed via Health Assessment Questionnaire Disability Index (HAQ-DI). The outcomes were assessed at baseline and every 3 months during 1 year of therapy. Among the 41 patients included initially, 2 participants discontinued the treatment after 1 month due to adverse events (elevation of liver enzymes). The study cohort exhibited a significant improvement in HAQ-DI, VAS-R and VAS-DU scores in response to Bosentan therapy over the 1-year follow-up period. Higher scores at baseline predicted a weaker treatment-related improvement, with the risk of a poor outcome being increased by 220% for VAS-R, 116% for VAS-DU, whereas no increase was observed for HAQ-DI. The post-treatment improvement in VAS-DU levels was associated with a better outcome for HAQ-DI (R=0.44; P=0.005). This association was not identified for VAS-R (R=0.24; P=0.137). Throughout the follow-up period, patients with dyspnea presented with significantly higher HAQ-DI scores compared with non-dyspneic patients. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and DU-related symptoms. Nonetheless, patients with SSc with a decreased symptom burden at baseline exhibited improved outcomes.

show abstract